PCP. R. Chowdhury

P. R. Chowdhury

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


P. R. Chowdhury has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combination of Hyaluronic Acid, Chondroitin Sulphate, and Poloxamer 407 for the Prevention and Treatment of Radiation Esophagitis (Results of the RESOXX Multicenter Prospective Observational Study)

    by D. S. Romanov, E. I. Turyaeva, S. N. Novikov, S. V. Golub, M. A. Ilin, D. A. Balaeva, G. A. Garyaev, P. R. Chowdhury, I. A. Cheremisina, M. A. Getman, et al.

    Aim: to evaluate the efficacy of an oral medical device — a fixed combination of hyaluronic acid, chondroitin sulphate, and the bioadhesive agent poloxamer 407 (Alfasoxx), on the incidence, course, and severity of radiation esophagitis symptoms in patients undergoing external beam radiotherapy for a primary malignancy. Materials and methods. A total of 215 patients were enrolled in the study, of whom 210 were included in the statistical analysis. Patients were divided into two groups: a treatment group (patients with manifestations of radiation esophagitis at study entry) and a prophylaxis group (patients enrolled on the start date of external beam radiotherapy). Seventeen oncologists from nine Russian cities participated in the study. Assessment methods included clinical and demographic evaluation, analysis of the incidence and distribution of radiation esophagitis risk factors, evaluation of radiation esophagitis severity according to CTCAE v. 5.0, assessment of radiation dose delivered to the esophagus, Alfasoxx dosage accounting for compliance, evaluation of the time to radiation esophagitis onset and its duration, analysis of swallowing function using the EAT-10 questionnaire, assessment of overall health-related quality of life using the EORTC QLQ-C30 questionnaire, and monitoring of adverse events. Results. Manifestations of radiation esophagitis were observed in 68.5 % of patients in the prophylaxis group; therefore, radiation esophagitis did not develop in 31.5 % of patients. Compared with the prophylaxis group, patients in the treatment group experienced a more severe course of the disease, with a mean radiation esophagitis severity score of 0.83 ± 0.53 vs. 0.52 ± 0.25 (p < 0.001). The mean EAT-10 score at baseline differed from that in the treatment group. However, from Visit 2 onward, mean scores aligned and demonstrated identical dynamics. A similar distribution was observed for overall quality of life as assessed by the EORTC QLQ-C30 questionnaire. The significant difference observed at the first visit (68.73 ± 15.69 points in the prophylaxis group vs. 58.24 ± 16.04 points in the treatment group; p < 0.001) was leveled by Visit 4 among patients who developed radiation esophagitis (79.96 ± 10.91 points in the prophylaxis group and 81.25 ± 11.03 points in the treatment group). Only one adverse event was identified during Alfasoxx administration: mild nausea after intake. Conclusion. The prophylactic administration of Alfazox concurrently with the initiation of external beam radiotherapy reduces the mean severity of radiation-induced esophagitis and shortens the duration of symptom manifestation.

  • Correction of anemia and mitochondrial dysfunction by iron citrate «Sintezit» during neoadjuvant chemotherapy for colorectal cancer and lymphoproliferative disorders

    by O.SH. Oinotkinova, E.L. Nikonov, A.I. Pavlov, O.M. Maslennikova, P.R. Chodvhuri, A.A. Ershov

    Iron deficiency is prevalent in one-third of cancer patients and rises to 90% during chemotherapy. The importance of targeted nutritional correction with iron is emphasized in the preoperative and chemotherapy phases. Objective. To assess the impact of iron citrate «Sintezit» on anemic mitochondrial disorders and chemotherapy tolerance in colorectal cancer and lymphoproliferative diseases. Materials and methods. Ninety-nine patients receiving chemotherapy were divided into three groups: the first group — 38 patients with stage II colorectal cancer, the second group — 42 patients with lymphoproliferative diseases, 19 patients in the third group — control with oncopathology without iron citrate therapy. Iron citrate «Syntezit» was administered orally, 10 drops under the tongue once a day throughout the course of chemotherapy. Biochemical and clinical blood parameters, indicators of lipid peroxidation (LPO), antioxidant defense enzymes (ADE), mitochondrial enzymes, ECG, echocardiography, pulse oximetry were assessed in dynamics. The clinical and overall condition were evaluated using a questionnaire. Results. Both groups showed improvement in overall well-being, alleviation of asthenia, increased physical endurance and appetite, enhanced sleep, absence of dyspepsia, and mitigation of tachycardia and shortness of breath. As a result of iron citrate therapy, 99.7% of patients experienced an increase in hematocrit, hemoglobin, iron, ferritin, transferrin, erythropoietin, and mitochondrial enzymes. Reduction in POL, elevation in ADE, normalization of hemorheological parameters, and improved myocardial contractility with increased ejection fraction were also noted. Conclusion. Iron citrate «Sintezit» contributes to enhanced mitochondrial function, increased arterial blood oxygen saturation, ATP production, and positive effects on biochemical and metabolic parameters.

  • Esophagopleural fistula complicated by pyopneumothorax in a patient with gray zone lymphoma

    by P.R. Chowdhury, I.L. Fedotova, S.V. Shamansky, D.A. Matveev, P.A. Zhuravlev, E.N. Solodinina, I.O. Ivanikov, N.S. Politov, M.E. Zharova

    Пищеводно-респираторные свищи — редкие осложнения различных злокачественных новообразований пищевода и легких, еще реже они возникают при лимфопролиферативных заболеваниях. В статье представлено описание клинической картины, методов диагностики и лечения пищеводно-плеврального свища у пациента с лимфомой «серой» зоны. Пациент Б., 33 года, с лимфомой серой зоны, осложненной развитием пищеводно-плеврального свища, госпитализирован в гематологическое отделение ФГБУ «ЦКБ с поликлиникой» Управления делами Президента Российской Федерации в тяжелом состоянии. Лечение включало химиотерапию, стентирование пищевода и нутритивную поддержку. Примечательно, что закрытие пищеводно-плеврального свища произошло одновременно с ответом пациента на химиотерапию, что подтверждается полным метаболическим ответом при проведении позитронно-эмиссионной томографии. Сочетание лимфомы «серой» зоны и пищеводно-плеврального свища делает этот случай уникальным, поскольку пищеводно-респираторные свищи при лимфомах встречаются редко, и тактика ведения данных пациентов до конца не определена. Успешное лечение пищеводно-плеврального свища в этом случае посредством комбинации стентирования пищевода и химиотерапии подчеркивает потенциал мультидисциплинарного подхода в таких сложных случаях. Этот подход способствовал эффективному разрешению пищеводно-плеврального свища без необходимости обширных хирургических вмешательств, связанных с высоким риском осложнений.